刘占伟,潘跃银

• 1:淮南东方医院集团肿瘤医院肿瘤内科
• 2:安徽医科大学第一附属医院肿瘤内科

摘要(Abstract)：

目的评估中等剂量卡培他滨单药一线治疗激素受体阴性老年女性转移性乳腺癌(metastatic breast cancer,MBC)的疗效和安全性。方法 32例初治激素受体阴性老年女性MBC患者,口服卡培他滨2 000 mg/(m2·d),分早、晚2次,餐后服用,连续服用2周,休息1周,为1个周期,服药≥2周期。结果 32例患者共完成204周期的化疗,其中CR 1例(3.1%),PR 10例(31.3%),RR为34.4%(95%CI:18.6%~53.2%),DCR为87.5%(95%CI:71.0%~96.5%)。卡培他滨治疗乳腺癌软组织转移及肝、肺转移的疗效差异无统计学意义(P=1.0)。常见的不良反应是手足综合征。至随访结束,中位TTP为8.5月,中位OS为17.5月。结论单药卡培他滨在老年女性初治MBC患者中较为有效且耐受性良好。

关键词(KeyWords)： 乳腺肿瘤/药物疗法;乳腺肿瘤/继发性;脱氧胞苷/投药和剂量;脱氧胞苷/类似物和衍生物;绝经期;治疗结果;随访研究

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 刘占伟,潘跃银

DOI: 10.13267/j.cnki.syzlzz.2015.03.020

参考文献(References)：

• [1]Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
• [2]Trotti A,Colevas AD,Setser A,et al.CTCAE v3.0:development of a comprehensive grading system for the adverse effects of cancer treatment[J].Semin Radiat Oncol,2003,13(3):176-181.
• [3]胡夕春.肿瘤内科方案的药物不良反应及对策[M].北京:人民卫生出版社,2009:447.
• [4]汤钊猷.现代肿瘤学[M].上海:复旦大学出版社,2011:1021.
• [5]Hamakera ME,Seynaeve C,Wymenga ANM,et al.Baseline comprehend-sive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy:Results from the OMEGA study of the Dutch Breast Cancer Trialists'Group[J].Breast,2014,23(1):81-87.
• [6]Palmeri S,Berretta M,Palmeri L.Medical treatment of elderly patients with breast cancer[J].Anti-Cancer Agents Med Chem,2013,13(9):1325-1331.
• [7]Cartwright TH.Treatment decisions after diagnosis of metastatic colorectal cancer[J].Clin Colorectal Cancer,2012,11(3):155-166.
• [8]Bang YJ.Capecitabine in gastric cance[J].Expert Rev Anticancer Ther,2011,11(12):1791-1806.
• [9]Wang Y,Yang H,Wei JF,et al.Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer:results from ten randomized trials[J].Curr Med Res Opin,2012,28(12):1911-1919.
• [10]Kaufmanna M,Maass N,Costa SD,et al.First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active:Results of the MONICA trial[J].Eur J Cancer,2010,46(18):3184-3191.
• [11]Smorenburg CH,de Groot SM,van leeuwen-Stok AE,et al.A randomized phaseⅢstudy comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer:results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG[J].Ann Oncol,2014,25(3):599-605.
• [12]Ershler WB.Capecitabine monotherepy:safe and effective treatment for metastatic breast cancer[J].Oncologist,2006,11(4):325-335.
• [13]Liu XH,Man YN,Cao R,et al.Individualized chemotherapy based on organ selectivity:a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer[J].Curr Med Res Opin,2014,30(6):1017-1024.
• [14]Zhou Y,Peng L,Li YJ,et al.Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome:A meta-analysis[J].Biomedical Reports,2013,11(6):873-878.
• [15]Macedo L,TLima JP,Dos Santos LV,et al.Prevention strategies for chemotherapy-induced hand-foot syndrome:a systematic review and meta-analysis of prospective randomised trials[J].Supportive Care Cancer,2014,22(6):1585-1593.